bluuebunny/crossref_metadata_2025_split huggingface dataset:
B-045 Evaluation of the Analytical Performance of Three Sepsis Related Assays on the Atellica CI Analyzer
Authors: Frenna J , Lee H , Tyler C , Arrode-Bruses G , Leipold H , Snyder J 
Published: October 2024

Abstract

Background
The Atellica® CI Analyzer is an automated, high-throughput integrated chemistry and immunoassay analyzer utilizing both Atellica® CH and Atellica® IM Assays. This study evaluated the analytical performance of the Atellica IM BRAHMS Procalcitonin (PCT) Assay, and the Atellica CH Revised C-Reactive Protein (RCRP) and Lactate_3 (Lac_3) Assays on the Atellica CI Analyzer.

Methods
Precision studies were performed according to CLSI EP05-A3 using native and contrived human serum (PCT, RCRP) or plasma and cerebrospinal fluid (Lac_3) samples. One aliquot of each sample pool was tested in duplicate in two runs per day ≥2 hours apart on each analyzer for ≥20 days. Precision studies were evaluated with one to three lots of reagent on one to two systems. Method comparison (MC) studies were performed using three reagent lots according to CLSI EP09c. Individual native and contrived human serum (PCT, RCRP) or plasma and cerebrospinal fluid (Lac_3) samples were analyzed using the Atellica IM PCT Assay on the Atellica IM Analyzer, the Atellica CH RCRP, Lac_3 Assays on the Atellica CH Analyzer and all three Atellica IM and CH Assays listed above on the Atellica CI Analyzer.

Results
Representative precision and MC results for each assay are listed in the table. For the three assays tested, repeatability and within-lab %CVs were &lt;1.4% and &lt;8.9%, respectively. Slopes determined by the Deming linear regression model were approximately equal to 1.

Conclusions
Evaluation of the Atellica IM PCT and Atellica CH RCRP, Lac_3 Assays using the Atellica CI Analyzer demonstrated good precision and equivalent performance compared to the same assays on their respective Atellica CH and Atellica IM Analyzers.
B-110 Descriptive Analysis of Multiple Myeloma Participants in the NIH All of Us Research Program Cohort: Insights into Demographics Disparities
Authors: Houze T A , Azuine R E , Mack N , McClain J , Lunt C , Denny J C 
Published: October 2024

Abstract

Background
Multiple Myeloma (MM) is a complex hematological malignancy characterized by significant heterogeneity in participant characteristics and treatment responses. The All of Us Research Program seeks to enroll 1 million diverse participants who share multiple sources of data, providing unique opportunities for research. A comprehensive descriptive analysis of MM participants within Electronic Health Records (EHR) databases can provide valuable insights into the disease's epidemiology, participant demographics, comorbidities, and treatment outcomes.

Objective
Using AI/ML predictive analytics, this study conducted a detailed descriptive analysis of MM participants’ EHR data in the All of Us Research Program cohort, which is enrolling 1 million diverse participants who share multiple sources of data.

Methods
We extracted data for participants diagnosed with MM from an extensive EHR database. The analysis included participant demographics (age, gender, race, ethnicity), diagnostic laboratory tests (SPEP, UPEP, CBC, renal function), comorbidities (renal impairment, bone disease, anemia, cardiovascular diseases), treatment details (chemotherapy, stem cell transplantation), and genetic markers (cytogenetic abnormalities).

Results
The analysis revealed diverse demographic patterns and a wide range of comorbidities associated with MM (Table 1).

Conclusions
The analysis demonstrated marked disparities in MM prevalence among African Americans and “More than one race,” revealing social and medical disparities. Implications: By understanding the diverse profiles of MM participants, stakeholders can more effectively address disparities in healthcare outcomes (1).
Reference:
1. Zeng, C., Schlueter, D. J., Tran, T. C., Babbar, A., Cassini, T., Bastarache, L. A., & Denny, J. C. (2024). Comparison of phenomic profiles in the All of Us Research Program against the US general population and the UK Biobank. Journal of the American Medical Informatics Association. Retrieved from, https://doi.org/10.1093/jamia/ocad260
B-164 Comparison of Analytical Performance of Two Processing Methods for Measurement of Zinc and Copper on Triple Quadrupole Inductively Coupled Plasma Mass Spectrometer
Authors: Oyelakin-Ogunbileje J O , Dahal R A , Zimmerman M K 
Published: October 2024

Abstract

Background
Copper (Cu) and zinc (Zn) are essential cofactors of enzymes involved in several metabolic processes required for the development of tissue structures and immune response, especially in pediatrics and pregnant women. Triple quadrupole inductively coupled plasma mass spectrometer (ICP-QQQ) enables simultaneous precise quantification of multiple elements with high throughput, sensitivity, and specificity. Samples are introduced into ICP-QQQ as a liquid and converted to fine aerosol with the help of a nebulizer and spray chamber. The precision and sensitivity of measured metals are dependent on the sample preparation thus, this study focuses on comparing the analytical performances between two sample preparations: 0.5% nitric acid (HNO3) as the only diluent (Diluent A) versus a combination of 0.5% HNO3 along with 1% ethanol, 0.5% Ammonium hydroxide, 0.02% TritonX-100, and 0.1% HNO3 (Diluent B) for Cu and Zn metal analysis in serum using ICP-QQQ.

Methods
Twenty deidentified randomly selected patient serum samples were prepared with either diluent A or diluent B and analyzed by ICP-QQQ (Agilent 8900). Data were analyzed using EP Evaluator. Bland-Altman analysis was used to determine the agreement between the two sample preparations. Deming regression analysis was used to determine other analytical performances, such as the proportional and constant bias of Zn and Cu concentration.

Results
There was a bias of -4.8 and -3.0 between the two sample preparation methods when analyzing Cu and Zn, respectively. The mean of Cu-Diluent B versus Cu—Diluent A was 125.2 ± 28.3 µg/dL and 120.4 ± 29.8 µg/dL, respectively, with a slope of 1.070. Conversely, the Zn comparison study shows a lower slope (0.769) with a mean of 71.0 ± 20.5 and 68.0 ± 16.1 µg/dL for Zn-Diluent B and Zn-Diluent A, respectively.

Conclusions
Samples prepared with nitric acid solution only (Diluent A) appeared to show negative bias compared to Diluent B solution containing triton-X for both metals. However, the bias is within the total allowable error for zinc and copper. Importantly, Zn-sample analysis with diluent A (HNO3 only) shows a 23% proportional bias, which is absent with copper sample analysis. A larger study is needed to further compare several methods of sample preparation in ICP-QQQ analysis while leveraging simple preparation without compromising analytical sensitivity. Overall, this study shows that both methods of sample preparation can be effectively used in the ICP-QQQ analysis of serum copper and zinc.
B-178 A Sensitive LC-MS/MS Assay for Total Testosterone Quantification
Authors: Cao W , Wolken J K , Peterson M M , Challoner K E , Jin Z 
Published: October 2024

Abstract

Background
Total testosterone immunoassay is a commonly ordered test for the diagnosis of gonadal disorders. However, immunoassays suffer from low specificity and sensitivity, which leads to inaccuracy especially in the low concentration range (&lt; 100 ng/dL). As a result, commercial testosterone immunoassays have difficulties to accurately measure total testosterone levels for women, children, and hypogonadal men. LC-MS/MS has emerged as the method of choice for the accurate quantitation of steroid hormones. We presented here a sensitive laboratory-developed total testosterone assay, which was validated on two LC-MS/MS instruments.

Methods
An internal standard containing [2,3,4-13C3]-testosterone was added to each sample. The spiked serum sample was loaded on a supported liquid extraction (SLE) cartridge and eluted using methylene chloride. The elute was dried down under nitrogen and reconstituted in sample reconstitution buffer. Chromatographic separation was achieved using a Restek Ultra C18, 50 x 2.1 mm, 3µm analytical column and a total run time of each sample was 5 minutes. The assay was validated on two triple quadrupole mass spectrometers, API 6500 and API 4500. Results were compared with those of a reference laboratory.

Results
The assay was linear in the range of 1 to 1200 ng/dL for total testosterone and the AMR was set at 2-1200 ng/dL. The interday and intraday imprecision were less than 8%. Split sample comparison to a reference laboratory demonstrated acceptable accuracy with the slope of 1.053 and correlation coefficient (R2) of 0.991. The limit of detection (LOD) was 0.2 ng/dL and the limit of quantitation (LOQ) was 0.5 ng/dL. Results obtained from two instruments agreed well with the slope of 0.996 and the R2 of 0.999. No carryover or interferences was observed for this assay.

Conclusions
A LC-MS/MS based method was developed and validated for measuring total testosterone levels for female and children. This sensitive and specific assay will improve the diagnosis of hypogonadism and monitoring of testosterone-suppressing treatment.
B-220 Clinical Application of the “Clg-Fish” Technique for the Diagnosis of Multiple Myeloma
Authors: Eduardo Levi J , Correa Wengerkievicz Lopes A , Maia C A , Silva A M , Renault I Z , Ramos R M , Passos J V , Andrade C F , Silva E V , Gomes D M , Argolo S V , Castelo M C 
Published: October 2024

Abstract

Background
The international standard system [R2-ISS] for Multiple Myeloma (MM) includes genetic characteristics of malignant cells by fluorescent in situ hybridization -t(4;14), del(17p) and t(14;16) at diagnosis; We included interphase fluorescent in situ hybridization (cIg-FISH) of purified CD138 cells in this evaluation. The aim of this study is to evaluate the implementation of cIg-FISH in MM for disease diagnosis and stratification.

Methods
oBone marrow [BM] from patients with MM diagnosed by the European Myeloma Network (REM) criteria were evaluated. BM mononuclear cells obtained by density gradient centrifugation for 30 minutes, with Ficoll-Hypaque density medium; followed by immunoassay with anti-Kappa/anti-Lambda antibodies labeled with FISH probes. We detected the following abnormalities: t(4;14), t(14;16) and deletion of 17p13. The t(11;14) and the amplification/deletion of 1q21-q22 (CKS1B)/1p32.3 (CDKN2C). We used the probes: TP53, IGH::FGFR3, IGH::CCND1, IGH:MAF and CKS1B/CDKN2C, one hundred cells per probe. Signals exceeding the cutoff recommended by REM were considered abnormal. The viability of the method was tested on samples 24, 48 and 72 hours after collection.

Results
Genetic aberrations seen in 24 and 48 hs plasma cells, a specific rearrangement of 14q32.33 t(4;14) in the 48 hs sample; Samples processed for 72 hours resulted in cells that were unviable for analysis. Genetic aberrations were detected by cIg-FISH in cells from 40% of patients. We detected the following abnormalities t(4;14) (Fig.1A), del(17p) (Fig. 1B); deletion of 1p32.3 amplification (CDKN2C) 1q21 (Fig. 1 C-D). The cIg-FISH study detected genetic aberrations in MM as those recommended by the European Myelomat Network - t(4;14), t(14;16) and del(17p), by FISH analysis for risk stratification for MM.

Conclusions
The inclusion of cIg-FISH in risk stratification systems has clinical relevance because cIg-FISH is a standard tool for detecting genetic abnormalities and prognosing the disease.
B-345 The PSA and free PSA Concentrations in Serum of Apparently Healthy Subjects Using the Atellica IM hsPSA and fPSAII Assays
Authors: Olson Nissen K , Snyder J , Pagano M , Owusu A , Grosett M , Birmingham N , Christenson R , deFilippi C 
Published: October 2024

Abstract

Background
PSA assays are recommended in the screening for prostate cancer (PC) among males 50 years and older. Those with PSA results in the gray zone (between 4 ng/mL and 10 ng/mL) and a nonsuspicious digital rectal examination (DRE) may be further tested with the free PSA (fPSA) assays to improve detection of PC. PSA and fPSA are also detected in apparently healthy subjects. The goal of this study was to evaluate the distribution of high sensitivity PSA (hsPSA), fPSAII, and %fPSAII (fPSAII/hsPSA x 100) values generated on the Atellica® IM Analyzer among apparently healthy subjects by age decade.

Methods
Serum samples were prospectively collected from apparently healthy subjects at multiple sites across the United States: 673 males 50-70+ years presenting at primary care facilities for routine PSA testing (&gt;120 samples in each age decade (50-59, 60-69, 70+ years) and 113 samples in each of two younger decades (30-39, 40-49 years). Distribution statistics include the mean, median, interquartile range, 2.5th, 95th, and 97.5th percentiles.

Results
In this study, using samples from healthy men 30-70+ years (N=786), it was observed that median hsPSA results increased with every decade from 0.682 ng/mL at 30-39 years to 2.183 ng/mL at age 70+ years. The 97.5th percentiles were below 4.0 ng/mL in men &lt;50 years, and above 4.0 ng/mL in men &gt;50 years. All men (100%) 30-49 years had an hsPSA result below 4.0, and 95.5% of men 50-59 years had an hsPSA result below 4.0. The percent of subjects with hsPSA values above the cut-off of 4.0 was 6.6% among men 60-69 years and 12.4% among men &gt;70 years. Median hsPSA values for each age group were comparable to median PSA values reported for healthy men older than 50 years old without cancer undergoing routine health check-ups in the United States and other countries (median hsPSA value was 0.90 among men 50-59 years). For both hsPSA and fPSAII, it was observed that average values increased with each successive decade for subjects 30-70+ years. The range across decades was 0.904-2.183 ng/mL for hsPSA and 0.23-0.46 ng/mL for fPSAII. However, the average %fPSAII (fPSA/hsPSAx100) values did not consistently rise over time because hsPSA variances also increase, a pattern previously documented.

Conclusions
The distribution of Atellica® IM hsPSA and fPSAII assay values from apparently healthy males was determined.
CAUTION: Investigational Device. Not available for sale. Future availability cannot be guaranteed. The results are preliminary and were achieved in unique setting with no expected timeline for completion.
B-355 Assessment of Calcitonin Cutoff Values for Post-Thyroidectomy Surveillance in Patients with Medullary Thyroid Carcinoma: Findings from a Single-Center Investigation
Authors: Li S , Patton A , Lee J K , Scheidegger M , Azaryan I , Sipos J , Nabhan F , Jones J , Algeciras-Schimnich A , Ringel M D 
Published: October 2024

Abstract

Background
Patients with sporadic or hereditary Medullary Thyroid Carcinoma (MTC) often undergo total thyroidectomy and lymph node dissection, with postoperative surveillance relying on serum calcitonin levels and ultrasound examinations. According to American Thyroid Association (ATA) guidelines, detectable levels of serum calcitonin and Carcinoembryonic Antigen (CEA) post-thyroidectomy suggest potential disease persistence or recurrence, necessitating frequent monitoring for early detection. This study sought to reassess the role of postoperative calcitonin levels in identifying possible tumor recurrence.

Methods
A retrospective analysis was conducted using Siemens Atellica to test calcitonin levels in 562 samples collected between 09/27/2022 and 08/11/2023, at least 3 months post-total thyroidectomy. Imaging studies performed within 6 months of the calcitonin assessment were also reviewed. Sample pools with calcitonin concentrations near 3.00 and 5.00 pg/mL were utilized to determine the limit of quantification (LoQ). CEA results were included for comparison. Additionally, 16 serum samples were analyzed using the Roche Cobas system at a reference laboratory.

Results
Precision analysis around 3.00 and 5.00 pg/mL revealed coefficients of variation (CVs) of 16.49% and 8.87%, respectively. Comparison of calcitonin levels between Siemens Atellica and Roche Cobas systems demonstrated consistent levels &lt; 5.00 pg/mL in 15 out of 16 samples, indicating alignment and reliability between the platforms. A calcitonin cutoff of 1.89 pg/mL yielded 43% sensitivity and 67% specificity, while a cutoff of 5.00 pg/mL resulted in 0% sensitivity and 100% specificity.

Conclusions
Our findings suggest that a 5 pg/mL calcitonin cutoff on the Siemens Atellica platform may be suitable for identifying tumor persistence or recurrence in post-thyroidectomy patients within our institution. However, individual laboratories should establish their LoQ criteria when interpreting calcitonin levels for postoperative monitoring of tumor recurrence.
Clock drift corrections for large aperture ocean bottom seismometer arrays: application to the UPFLOW array in the mid-Atlantic Ocean
Authors: Cabieces R , Harris K , Ferreira A M G , Tsekhmistrenko M , Hicks S P , Krüger F , Geissler W H , Hannemann K , Schmidt-Aursch M C 
Published: September 2024

SUMMARY
Accurate timing corrections for seismic data recorded by ocean bottom seismometers (OBSs) are essential for a wide range of applications. The synchronization of internal OBS clocks with Global Positioning System (GPS) is typically only possible prior to deployment on the seafloor and upon retrieval. Thus, untracked, clock errors in seismic data may accumulate over the deployment period. The measurement of the clock's offset from GPS at retrieval, referred to as ‘skew’, can be used to correct the data solely under the assumption of a uniform rate of clock drift throughout the whole deployment. However, clock errors can be non-linear. We, therefore, develop a new workflow along with an associated open-source, interactive graphical user interface to estimate clock drift of large aperture OBS arrays. We use the workflow to estimate OBS clock drift curves for 40 OBSs of the large-scale UPFLOW seafloor array in the Madeira–Azores–Canaries region deployed for ∼14 months in 2021–2022. We use the relative shift of daily empirical Green's functions obtained from seismic ambient noise recorded by all available data channels to track clock error. We find that 95 per cent of our OBS clock drift observations have a substantial non-linear component: most maximum deviations to linearity are ∼0.75–1 s (and up to 2 s) occurring mainly halfway through the deployment. We test our drift curves by using them to correct teleseismic earthquake recordings, which enables larger numbers of high-quality P-wave traveltime measurements than when using linear drift corrections. Our drift curves have on average an uncertainty of ∼0.11 s indicating the suitability of the corrected data for future seismological studies such as for seismic tomography, seismicity analysis and moment tensor inversions.
Complete mitochondrial genome characterisation of Ratha longimana (H. Milne Edwards, 1834) from the western Atlantic Ocean, with a phylogeny of the Xanthidae (Decapoda: Brachyura)
Authors: van der Meij Sancia E T , Xu Tao 
Published: September 2024

Abstract
The longhand rubble crab Ratha longimana inhabits coral reefs and rocky shores in the subtropical and tropical western Atlantic Ocean. This species was long considered to be the only chlorodielline species present in the area, but has since been transferred to the genus RathaLasley, Lai & Thoma, 2013 and is now thought to belong to an undescribed subfamily within Xanthidae MacLeay, 1838. Here we provide a complete mitochondrial assemblage and characterisation of this species. The assembled mitochondrial genome (hereafter mitogenome) of R. longimana is 15,819 bp in length and contains 13 protein coding genes (PCGs), 22 transfer RNA (tRNA) genes, and two ribosomal RNA (rRNA) genes. The 22 tRNA genes range from 62 to 69 bp in length. A mitochondrial gene order (MGO) analysis revealed a transposition of the tRNA genes Val (V) and 12S rRNA (rrnS) when compared to the ancestral brachyuran gene order, which is in line with earlier studies on xanthoid mitogenomes. Mitogenome data for xanthid crabs (as well as the superfamily Xanthoidea MacLeay, 1838) are currently scarce considering the species richness of the family, limiting the options for phylogenomic studies. This is partially remedied here by providing a new genomic resource for R. longimana.
Revisiting the formaldehyde masers – II. Effects of an H ii region and beaming
Authors: van der Walt D J 
Published: September 2024

ABSTRACT
We present new results of a numerical study of the pumping of 4.8 and 14.5 GHz maser of o–$\mathrm{H_2CO}$ in the presence of a free–free radiation field. It is shown that in the presence of a free–free radiation field inversion of not only the $1_{10}{\!-\!}1_{11}$, but also the $2_{11}{\!-\!}2_{12}$ and other doublet state transitions occur. Further results are presented to illustrate how, as a consequence of the pumping scheme, the inversion of the $1_{10}{\!-\!}1_{11}$ and $2_{11}{\!-\!}2_{12}$ transitions respond to the free–free radiation fields associated with H ii regions with different emission measures and levels of geometric dilution with respect to the masing region. We also discuss the criticism raised in the past by various authors against the pumping of the 4.8 GHz $\mathrm{H_2CO}$ masers by a free–free radiation field. It is argued that the rarity of the $\mathrm{H_2CO}$ masers is not to be ascribed to the pumping scheme but to other factors such as, e.g. the evolution of the associated H ii region or the chemical evolution of the star-forming region that determines the $\mathrm{H_2CO}$ abundance or a combination of both.
HGGL-01 GLIOBLASTOMA MULTIFORM INVOLVING MULTIPLE BRAIN REGIONS ASSOCIATED WITH MUTATIONS IN EXON 4 OF ISOCITRATE DEHYDROGENASE 1 COMPLICATED BY ACUTE KIDNEY FAILURE: A CASE REPORT
Authors: Kamabu Larrey Kasereka , Ronald Oboth , Paul Okiror , Kataka Louange , Lekuya Hervé , Valimungighe Moise , Kangitsi Charles Kahindo 
Published: October 2024

Abstract
Glioblastoma multiform (GBM), WHO grade 4, is the most aggressive primary brain tumor in adults associated with poor prognosis. We present a case of a 43-year-old female, Muyira, diagnosed with GBM involving multiple brain regions and harboring mutations in exon 4 of isocitrate dehydrogenase 1, who subsequently developed acute kidney failure. The patient initially presented with progressive neurological symptoms, including headache and cognitive decline. Multiplanar multiecho MRI of the brain was performed with IV contrast in orthogonal plane and revealed a moderate sized multilobulated heterogeneously and predominantly peripherally enhancing mass lesion with irregular margins and central non enhancing areas of necrosis arising from the right corona radiata, insular cortex, external capsule, lentiform nucleus, temporal, and frontal white matter with blood products. Perilesional edema was seen. Effacement of sulcal spaces. Right sylvian fissure, compression over right ventricle and midline shift of 8mm toward left side. There was dilatation of the left lateral ventricle with periventricular cerebrospinal fluid ooze. Uncal herniation was right side. On MR spectroscopy large choline, creatinine levels were seen in the lesion with reduced N-acetyl aspartate levels as compared to the normal parenchyma. Findings were suggestive of neoplastic lesion mostly high-grade glioma. Polymerase chain reaction sequencing confirmed the presence of missense mutation R132H in exon 4 of isocitrate dehydrogenase 1 gene. Despite maximal safe surgical resection, the patient developed acute kidney failure secondary to the nephrotoxic effects of gadolinium. Management of both the primary brain tumor and renal complication necessitated a multidisciplinary approach involving neurosurgery, oncology, nephrology, and supportive care. Despite aggressive interventions, the patient’s condition deteriorated, highlighting the challenges in managing concurrent life-threatening conditions in patients with advanced GBM.